XCR1 and neoplasm: Tumor growth and survival were monitored, and immune infiltrates were analyzed using flow cytometry or scRNA-seq.<h4>Results</h4>Tumor rejection was impaired when SHP-1 was depleted in CD11c<sup>+</sup> cells, as well as in XCR1<sup>+</sup> or Lyz2<sup>+</sup> cells.